Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Pasternak Andy | EVP, Chief Strategy Officer | Jan 17 | Sale | 113.03 | 27,129 | 3,066,323 | 56,338 | Jan 18 04:19 PM | Cox Aaron | EVP, Chief Financial Officer | Jan 13 | Sale | 113.17 | 36,148 | 4,090,847 | 277 | Jan 17 08:32 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Jan 11 | Sale | 113.10 | 3,368 | 380,921 | 36,171 | Jan 12 04:29 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Jan 10 | Sale | 113.05 | 3,368 | 380,752 | 39,539 | Jan 12 04:29 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Jan 06 | Sale | 113.29 | 5,187 | 587,635 | 49,314 | Jan 06 05:54 PM | Pasternak Andy | EVP, Chief Strategy Officer | Dec 13 | Option Exercise | 29.52 | 23,251 | 686,370 | 64,216 | Dec 14 05:10 PM | Pasternak Andy | EVP, Chief Strategy Officer | Dec 13 | Sale | 112.60 | 30,169 | 3,397,171 | 34,047 | Dec 14 05:10 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Dec 12 | Sale | 111.45 | 28,352 | 3,159,692 | 54,501 | Dec 13 04:12 PM | Clayton Sean M. | EVP, General Counsel | Aug 04 | Buy | 66.67 | 745 | 49,669 | 745 | Aug 08 04:18 PM | Pasternak Andy | EVP and Chief Business Officer | Jul 29 | Sale | 82.57 | 4,850 | 400,483 | 34,047 | Jul 29 05:21 PM | Thompson Elizabeth H.Z. | EVP, Research & Development | Jul 20 | Sale | 85.00 | 5,917 | 502,945 | 6,969 | Jul 20 06:19 PM | Thompson Elizabeth H.Z. | EVP, Research & Development | Jul 19 | Sale | 85.04 | 90 | 7,653 | 12,886 | Jul 20 06:19 PM | Thompson Elizabeth H.Z. | EVP, Research & Development | Jul 07 | Sale | 85.01 | 82 | 6,971 | 12,976 | Jul 11 06:03 PM | Pasternak Andy | EVP and Chief Business Officer | Jun 10 | Sale | 85.36 | 762 | 65,044 | 38,897 | Jun 13 04:19 PM | Walbert Timothy P | Chairman, President and CEO | Jun 03 | Option Exercise | 22.14 | 25,000 | 553,500 | 460,826 | Jun 03 07:04 PM | Walbert Timothy P | Chairman, President and CEO | Jun 03 | Sale | 92.34 | 25,000 | 2,308,468 | 435,826 | Jun 03 07:04 PM | Walbert Timothy P | Chairman, President and CEO | May 31 | Sale | 92.48 | 25,000 | 2,311,980 | 435,549 | Jun 02 04:13 PM | Walbert Timothy P | Chairman, President and CEO | May 20 | Option Exercise | 22.14 | 25,000 | 553,500 | 485,549 | May 20 06:15 PM | Walbert Timothy P | Chairman, President and CEO | May 20 | Sale | 90.00 | 25,000 | 2,250,000 | 460,549 | May 20 06:15 PM | Walbert Timothy P | Chairman, President and CEO | May 11 | Option Exercise | 22.14 | 17,600 | 389,664 | 478,149 | May 13 04:31 PM | Walbert Timothy P | Chairman, President and CEO | May 11 | Sale | 90.00 | 17,600 | 1,584,000 | 460,549 | May 13 04:31 PM | Walbert Timothy P | Chairman, President and CEO | May 06 | Option Exercise | 22.14 | 7,400 | 163,836 | 467,949 | May 10 05:59 PM | Walbert Timothy P | Chairman, President and CEO | May 06 | Sale | 90.86 | 7,400 | 672,342 | 460,549 | May 10 05:59 PM | Walbert Timothy P | Chairman, President and CEO | May 02 | Sale | 96.04 | 25,000 | 2,401,006 | 460,549 | May 04 04:24 PM | Walbert Timothy P | Chairman, President and CEO | Apr 22 | Option Exercise | 22.14 | 25,000 | 553,500 | 510,549 | Apr 22 06:49 PM | Walbert Timothy P | Chairman, President and CEO | Apr 22 | Sale | 106.59 | 25,000 | 2,664,632 | 485,549 | Apr 22 06:49 PM | Hoelscher Paul W. | EVP, CFO | Apr 20 | Option Exercise | 22.14 | 50,000 | 1,107,000 | 51,049 | Apr 22 06:47 PM | Hoelscher Paul W. | EVP, CFO | Apr 20 | Sale | 114.71 | 50,000 | 5,735,449 | 1,049 | Apr 22 06:47 PM | Thompson Elizabeth H.Z. | EVP, Research & Development | Apr 18 | Sale | 115.64 | 8,098 | 936,453 | 13,058 | Apr 20 04:13 PM | DesJardin Michael A. | EVP, Technical Operations | Apr 12 | Sale | 113.12 | 20,214 | 2,286,703 | 82,346 | Apr 14 04:49 PM | Walbert Timothy P | Chairman, President and CEO | Apr 08 | Option Exercise | 22.14 | 25,000 | 553,500 | 510,549 | Apr 08 04:11 PM | Walbert Timothy P | Chairman, President and CEO | Apr 08 | Sale | 112.38 | 25,000 | 2,809,521 | 485,549 | Apr 08 04:11 PM | Hoelscher Paul W. | EVP, CFO | Apr 06 | Option Exercise | 21.27 | 215,335 | 4,580,417 | 216,384 | Apr 08 04:09 PM | Hoelscher Paul W. | EVP, CFO | Apr 06 | Sale | 110.01 | 91,710 | 10,089,026 | 66,673 | Apr 08 04:09 PM | Hoelscher Paul W. | EVP, CFO | Apr 06 | Sale | 110.01 | 215,335 | 23,688,788 | 1,049 | Apr 08 04:09 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Apr 06 | Sale | 110.02 | 42,009 | 4,621,872 | 10,629 | Apr 08 04:07 PM | Walbert Timothy P | Chairman, President and CEO | Mar 30 | Sale | 105.26 | 50,000 | 5,262,787 | 485,549 | Apr 01 04:10 PM | Walbert Timothy P | Chairman, President and CEO | Mar 25 | Option Exercise | 22.14 | 25,000 | 553,500 | 560,549 | Mar 25 06:40 PM | Walbert Timothy P | Chairman, President and CEO | Mar 25 | Sale | 109.37 | 25,000 | 2,734,340 | 535,549 | Mar 25 06:40 PM | Hoelscher Paul W. | EVP, CFO | Mar 25 | Sale | 110.00 | 663 | 72,930 | 158,383 | Mar 25 06:38 PM | Hoelscher Paul W. | EVP, CFO | Mar 24 | Sale | 110.00 | 1,481 | 162,910 | 159,046 | Mar 25 06:38 PM | Hoelscher Paul W. | EVP, CFO | Mar 23 | Option Exercise | 15.96 | 26,090 | 416,396 | 27,139 | Mar 25 06:38 PM | Hoelscher Paul W. | EVP, CFO | Mar 23 | Sale | 110.01 | 11,699 | 1,287,018 | 160,527 | Mar 25 06:38 PM | Hoelscher Paul W. | EVP, CFO | Mar 23 | Sale | 110.00 | 26,090 | 2,870,002 | 1,049 | Mar 25 06:38 PM | SHERMAN JEFFREY W | EVP and Chief Medical Officer | Mar 18 | Option Exercise | 22.14 | 8,531 | 188,876 | 52,638 | Mar 21 04:25 PM | Walbert Timothy P | Chairman, President and CEO | Mar 11 | Option Exercise | 22.14 | 25,000 | 553,500 | 560,549 | Mar 11 05:17 PM | Walbert Timothy P | Chairman, President and CEO | Mar 11 | Sale | 100.93 | 25,000 | 2,523,314 | 535,549 | Mar 11 05:17 PM | DesJardin Michael A. | EVP, Technical Operations | Mar 02 | Sale | 97.19 | 35,000 | 3,401,752 | 102,560 | Mar 04 04:19 PM | Pasternak Andy | EVP and Chief Business Officer | Feb 18 | Sale | 94.82 | 1,313 | 124,499 | 39,659 | Feb 18 04:42 PM | Walbert Timothy P | Chairman, President and CEO | Feb 11 | Option Exercise | 22.14 | 25,000 | 553,500 | 610,549 | Feb 11 04:16 PM | Walbert Timothy P | Chairman, President and CEO | Feb 11 | Sale | 97.41 | 25,000 | 2,435,242 | 585,549 | Feb 11 04:16 PM |
|